Rao Naveen, Brotons-Munto Francisco, Moura Ana F, Kocks Janwillem W H, Zhao Ming-Hui, Chadban Steven, Guiang Hannah, Priest Stacey, Brown Stephen
BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Trinitat Health Center, Valencia, Spain.
Kidney Int Rep. 2025 Apr 2;10(7):2116-2127. doi: 10.1016/j.ekir.2025.03.051. eCollection 2025 Jul.
Chronic kidney disease (CKD) is a growing global health problem driven by aging and the rise of comorbidities, including diabetes and hypertension. Although clinical and economic burdens have been reported, there is a lack of information on the multidimensional impact of CKD across countries with varying demographics and health system archetypes.
The validated IMPACT CKD model was used to project the clinical, health care resource use (HCRU), economic, patient, societal, and environmental burden of CKD in 8 countries (Australia, Brazil, China, Germany, Netherlands, Spain, United Kingdom, and United States) over 10 years (baseline: 2022; simulated years: 2023-2032).
By 2032, 11.7% to 16.5% of the countries' populations were projected to have CKD, with prevalence rising in 7 countries over 10 years, and a shift toward later stages. These increases were accompanied by projected increases of 3.6% to 170.8% and 41.9% to 80.1% in the number of patients living on dialysis and with a functioning kidney transplant, respectively. Driven by this growing clinical burden, increases of over 19% in CKD costs and 20% in kidney replacement therapy (KRT) costs were projected across all countries. Impaired work productivity led to significant projected losses in gross domestic product, full-time equivalents, and tax revenue. Freshwater consumption, fossil fuel depletion, and carbon production in patients on KRT were projected to increase by over 11% in all the countries.
This study demonstrates the multifaceted burden of CKD globally and supports the adoption of policies such as CKD screening programs and public health awareness to promote early diagnosis and treatment to mitigate the growing disease burden.
慢性肾脏病(CKD)是一个日益严重的全球健康问题,其受到老龄化以及包括糖尿病和高血压在内的合并症增加的驱动。尽管已有关于临床和经济负担的报道,但对于不同人口统计学特征和卫生系统原型的国家中CKD的多维度影响,仍缺乏相关信息。
使用经过验证的IMPACT CKD模型,对8个国家(澳大利亚、巴西、中国、德国、荷兰、西班牙、英国和美国)未来10年(基线:2022年;模拟年份:2023 - 2032年)的CKD临床、医疗资源使用(HCRU)、经济、患者、社会和环境负担进行预测。
到2032年,预计这些国家11.7%至16.5%的人口将患有CKD,其中7个国家的患病率在10年内上升,且病情向晚期转变。随之而来的是,预计透析患者数量将增加3.6%至170.8%,有功能肾移植患者数量将增加41.9%至80.1%。受这一日益加重的临床负担驱动,预计所有国家的CKD成本将增加超过19%,肾脏替代治疗(KRT)成本将增加20%。工作生产力受损导致预计国内生产总值、全职等效人员数量和税收收入大幅损失。预计所有国家接受KRT治疗的患者的淡水消耗、化石燃料消耗和碳排放量将增加超过11%。
本研究展示了全球范围内CKD的多方面负担,并支持采取诸如CKD筛查计划和提高公众健康意识等政策,以促进早期诊断和治疗,减轻不断增加的疾病负担。